Member Info for CityTTrader

MAnabout. Think about your wait and see approach. You can buy now for 100p ish but you think you should wait for 200p? In other words miss out on doubling your investment. If you buy at 200p you will have to wait for 400p before doubling your money but if you buy tomorrow at 100p and wait for 400p then you will have increased your money by 300% not just 100%. I'm not saying either scenario will happen quickly but 200p could happen within the month. Its up to you.

AT least we can back up our arguments or points of view with facts. Meanwhile Zeb just sings mud.

TILS is with the 2 big company Covid-19 treatments, and TILS has already shown 2 distinct advantages over Roche's Actemra and Regeneron’s Kevzara. Hence why TILS has had to file the patent for this treatment very quickly. They have a major competitive advantage going forward - and none of this has been reflected in the previously over sold prices.

The recent news is that Ventilators are causing permanent lung damage, because they are forcing oxygen in, which is not being totally used by the lungs due to the lung infection. Therefore the infection has to be cleared or the patience dies. TILS targeting drug and procedure (superior) and targets the lungs to clear the infection that is actually causing death. :) / this is home run, considering to major drugs have worked in China and these are intravenous delivery only and do not deliver directly to the lungs. They also caused poor immune responses because they’re humanised and not like TILS drug which is human ready and will not have any impact on human immune system.

TZLS-501 by Tiziana Life Sciences

Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6.

The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation.

Actemra by Roche to treat coronavirus-related complications

China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus. Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure leading to death in some coronavirus patients.

Actemra is also being evaluated in a clinical trial in China, which is expected to enrol 188 coronavirus patients. The clinical trial is expected to be conducted until May 10.

Regeneron’s REGN3048-3051 and Kevzara

Discovered by Regeneron, the combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The safety and tolerability of the drug will be studied in 48 patients.

Both the antibodies bind to S-protein of MERS coronavirus. The intravenous administration of the drug in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs.

Regeneron has partnered with Sanofi to evaluated Kevzara, a fully-human monoclonal antibody, in a phase two/three clinical trial in patients with severe COVID-19 infection. Kevzara is approved for the treatment of rheumatoid arthritis and is known t

Hi Cloudy, Could you tell me where you have heard that a manuafactuter is ready to produce?

As to funding I see no real issue here. TILS has cash and will no doubt place some funds into the new company I call STEMP. Its highly unlikely to spin it off with no funding. How could it pay salaries etc without? Equally the LSE would not acce=pt a company onto its books without cash on its balance sheet. My understanding so far is that STEMP will have around £500k initially.

The record date will be at some point in the future not in the past. Remember this split hasn't even been voted upon by the shareholders yet.
My view is that this split will be soon picked up by the media and there will be a stampede to buy in. I would think we are about 3-6 months of an actual split though it could be speeded up. As some say someone might just come knocking before then.
All we have to do is to hold the shares we have and sit on our hands. Buy a dog, train it to bite you if you're about to press the sell button. That's all you need to do.

Y Alam WHta you have to understand is that these institutions don't react very quickly to such a position. To you and I its obviously a buy and we can decide to buy very quickly. Insti's though have a process of full research and then the decision has to go through a few people up the chain of command and then they make a decision. It takes a few days or weeks. We have the advantage its our money our decision.
I expect to see a good solid move in the next week though 100p possibly to 150p within the week..

I'm working it on the basis that for every share in TILS we get one share in tehe new company which I shall call STEM.
Recent valuations before StemPrinter was announced as being successful in trials were that TILS was worth about 320p a share. but Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6 so the 320p valuation could be meaningless. it could be closer to £10 a share. It all depends on what happens here.

The StemPrinter news that it was a 35-40% improvement on the current market leader kind of came out of nowhere. Nobody had really taken much notice of this product before then. STEM though can be valued pretty accurately because 6 months ago Exact Sciences paid £2.8bn for a similar but inferior product. if STEM is 160m shares then each share would be valued at £17.50 maybe more but not really less.
So we can place a current value on TILS of between £20-30 £20 without any COVID19 treatment £30 with.
It might take a year to reach these prices or it might be quicker but one thing is for sure and that is you don't ned to look at another share until this happens. It will be the easiest way you ever made money.

Its thinking about it.

Its all about price points like in retail. You price ites at say 10p, 20p, 30p, 40p, 50p 75p 100p 125p, 150p etc. Very rarely inbetween. SHares seem to have a similar pattern. Once we break through 100p then 125p will be the next sticking point.

TILS was going to delist becuase biotecs have a better rating in the USA. However a recent RNS stated that this is now delayed.

£120 might be a little high;-) I will settle for 120p today though.

My guess here is that TILS has had an approach for StemPrinter and suddenly realised that they are very vulnerable to a lowball offer. So now they need to do this split ahead of any delisting from AIM . Its a bit of a panic rush to suddenly do this so the new company will be on AIM and not NASDAQ. Something has spooked them..

TILS has £30m in the bank. I would guess that they would be letting the new company have some of that cashpile to get it started.

Before the StemPrinter news last week we had a rough valuation for the company at around £3.20. Then STemPrinter came along and suddenly billions beckoned.
If we recieve one share in the new company for every share we own then I calculate about £17.50 for the new share. So we could say every share has a current value of £20

Thats 64m share ish

Being tested right now

Yes I had the same thoughts when TW. went to 4p all because Aviva decided to dump them. AT the time TW. had a billion in debts and 4bn in assets. suddenly the company was worth £80m with £3bn true assets. It was an obvious buy and made good money

As the CEO says most people invested in TILs for other treatments and StemPrinter wasn't even on the radar until last week. Now that one product could be worth £17.50 for each share we hold.

We have just been given a dividend of £17.50 for a share you can buy for 100p. Easy multibagger.

SHareholders have to know first.

When GKP found its first huge reservoir The shares moved but not much from 14p I bought in at 17p on the same morning. SOld out at 125p a fonths later. This will gather steam no problem.

Remember £2.8 billion pounds paid by Exact SCiences for a 35-40% inferior product.

each new share could be worth £17.50 alone.